The third quarter was a busy quarter with strategic activities which we expect will have a positive effect on the company’s market value. These activities are reflected in our quarterly results (available in Hebrew and in English) presenting a capital gain of 7 million NIS. These activities included a raise of over 5 million NIS through a rights offering on the TASE with over 99% participation including a number of institutional investors. Portfolio companies have also had achievements such as a successful completion of a clinical trial by Enlivex and an investment of $3.5 M in CellCure.
Ophir Shahaf, CEO of Hadasit-Bio: "I expect that this trend will continue and we will continue to bring our companies closer to an exit.”
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Hadasit Bio-Holdings (“HBL”) and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will”, “believes”, “plans”, “anticipates”, “expects”, “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of HBL and its subsidiaries. HBL disclaims any intent or obligation to update these forward-looking statements.